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Here we describe the LifeTime Initiative, which aims to track, understand and target 
human cells during the onset and progression of complex diseases, and to analyse 
their response to therapy at single-cell resolution. This mission will be implemented 
through the development, integration and application of single-cell multi-omics and 
imaging, artificial intelligence and patient-derived experimental disease models during 
the progression from health to disease. The analysis of large molecular and clinical 
datasets will identify molecular mechanisms, create predictive computational models 
of disease progression, and reveal new drug targets and therapies. The timely detection 
and interception of disease embedded in an ethical and patient-centred vision will be 
achieved through interactions across academia, hospitals, patient associations, health 
data management systems and industry. The application of this strategy to key medical 
challenges in cancer, neurological and neuropsychiatric disorders, and infectious, 
chronic inflammatory and cardiovascular diseases at the single-cell level will usher in 
cell-based interceptive medicine in Europe over the next decade.
Although advances in medicine have led to remarkable progress in 
certain disease areas, most chronic disorders still cannot be completely 
cured. This is mainly because most such diseases are detected only 
late in their progression, once gross physiological symptoms manifest 
themselves, at which point tissues and organs have often undergone 
extensive or irreversible damage. At this stage, the choice of interven-
tions is typically quite limited. It is difficult to predict whether a patient 
will respond to a particular treatment (often invasive or aggressive 
therapies that can be of modest benefit), or whether therapy resistance 
will emerge and lead to a relapse. Despite technology-driven revolu-
tions that enable a patient’s physiology to be investigated at the level 
of molecules1,2 and placed in the context of tissues3,4, in most cases our 
ability to detect and predict diseases at an early stage is limited by our 
incomplete mechanistic understanding of disease at the cellular level.
Cells develop and differentiate along specific lineage trajectories 
to form functionally distinct cell types and states5, which, together 
with their neighbouring cells, underlie and control normal physiology 
(Fig. 1). However, we have not been able to systematically detect and 
understand the molecular changes that propel an individual cell 
along these trajectories during normal development or ageing, or the 
molecular causes that trigger deviations from healthy trajectories and 
drive cells and tissues towards disease (Fig. 1). Timely detection and 
successful treatment of disease will depend crucially on our ability to 
understand and identify when, why, and how cells deviate from their 
normal trajectories. More accurate cellular and molecular diagnostics 
will enable us to intercept disease sufficiently early to prevent irrepara-
ble damage. To achieve this interceptive medicine (Fig. 1), we need to 
invest in approaches that provide a detailed molecular understanding 
of the basis of disease-related heterogeneity in tissues, with sufficient 
molecular, cellular and temporal resolution.
Several challenges need to be overcome in order to understand com-
plex disease landscapes, which comprise of vast numbers of potential 
cellular states (Fig. 1). First, we need to resolve normal cellular hetero-
geneity across space and time to begin to define the cell types, states 
https://doi.org/10.1038/s41586-020-2715-9
Received: 29 April 2020
Accepted: 25 August 2020
Published online: 7 September 2020
Open access
 Check for updates
A list of affiliations appears at the end of the paper. *A list of members and their affiliations appears at the end of the paper.
378 | Nature | Vol 587 | 19 November 2020
Perspective
and cell–cell interactions that normally exist in the body. This is a main 
goal of the Human Cell Atlas consortium6. However, to discover the 
cellular bases of diseases requires that we track cellular heterogeneity 
and the molecular composition of cell trajectories in health and dur-
ing disease progression longitudinally—throughout an individual’s 
lifetime. Second, we need to understand the molecular mechanisms 
and complex networks that define a cell’s state, and control its func-
tion, fate and trajectory over time, to be able to reconstruct a cell’s 
history and predict its future. This is essential for selecting the optimal 
intervention for an individual patient. Thus, systematic and longitu-
dinal profiling of samples from many individuals is required. Third, 
we have yet to develop the computational frameworks required for 
integrating temporal data and patient profiles, with large cohorts to 
identify regulatory changes and to dissect the causes and manifesta-
tions of disease. Current attempts to model human disease have not 
succeeded in integrating the thousands of molecular phenotypes that 
are acquired from patients. Finally, we are limited by our lack of knowl-
edge of the underlying causes of disease. To predict any given patient’s 
response to a specific therapy may require testing or modifying cells 
from the patient in an experimental system, a challenge that has yet to 
be routinely implemented.
To address these challenges experts from different disciplines 
came together in 2018 to form the LifeTime Initiative (https://
lifetime-initiative.eu). It has since grown to be a pan-European com-
munity consisting of more than 90 research institutions with support 
from 80 companies and several funding agencies and national sci-
ence academies. In 2019 the initiative was awarded a Coordination and 
Support Action by the European Commission to develop a Strategic 
Research Agenda (SRA)7 for a large-scale, long-term initiative with a 
roadmap for implementing cell-based interceptive medicine in Europe 
in the next decade. The ambitious goal is the early detection and inter-
ception of complex diseases, as well as the ability to select the most 
effective therapeutic strategy for a patient. Between March 2019 and 
June 2020 the initiative established several multi-disciplinary working 
groups (listed in the Supplementary Information), organized numer-
ous workshops, meetings and surveys (and thereby engaged the wider 
community) and commissioned stakeholder interviews and an impact 
study. The European Commission will use LifeTime’s SRA during the 
planning of the next research and innovation framework programme: 
Horizon Europe. Here, we outline LifeTime’s vision and key aspects of 
the SRA towards establishing cell-based interceptive medicine.
Central to LifeTime’s vision and approach is the development and 
integration of new technologies, such as single-cell multi-omics, 
high-content imaging, artificial intelligence (AI) and patient-derived 
experimental disease models. The application of these integrated 
approaches to medical challenges and their incorporation into both 
experimental and clinical workflows are expected to directly benefit 
patients. For example, appropriate single-cell based biomarkers will 
give physicians early warning that a cell or tissue is entering a disease 
trajectory. Understanding disease heterogeneity at the cellular level 
and knowing the molecular aetiology of a disease will allow researchers 
to systematically identify drug targets and resistance mechanisms and 
to define therapeutic approaches, based on a given disease’s molecular 
or cellular vulnerability. This strategy differs markedly from classical 
approaches to drug discovery8. The stratification of patients on the 
basis of underlying disease mechanisms, assessed in situ within single 
cells, will help physicians to select the most appropriate treatment(s) or 
to use combination therapies that are tailored to the individual. These 
will be used first to identify cells that are deviating from the healthy 
trajectory, to steer them away from disease, and later to reduce the 
threat of relapse (Fig. 1). This transformative single-cell data-driven 
approach has the potential to increase the success rates of clinical tri-
als and the efficacy of novel therapeutic interventions in clinics over 
the next decade. Overall, the LifeTime strategy is likely to affect both 
diagnosis and treatment, to greatly improve health and quality of life, 
and to reduce the societal burden of diseases such as cancer, neurologi-
cal and neuropsychiatric disorders, infectious diseases, and chronic 
inflammatory and cardiovascular diseases.
Below, we outline the development and implementation of technol-
ogy at the heart of LifeTime’s approach, describe LifeTime’s mechanism 
for identifying medical priorities, discuss the required infrastructures 
in Europe, interactions with industry and innovation, ethical and legal 
issues, describe LifeTime’s education and training vision, and estimate 
the expected impact of the LifeTime approach on medicine and health-
care. LifeTime builds on and will collaborate with related international 
initiatives that are paving the way by producing reference maps of 
healthy tissues in the body, such as the Human Cell Atlas (HCA)6 and 
the NIH Human Biomolecular Atlas Program (HuBMAP)9.
Technology development and integration
Single-cell technologies—particularly transcriptomics—are generating 
the first reference cell atlases of healthy tissues and organs, and are 
revealing a previously hidden diversity of cell subtypes and functionally 
distinct cell states6. Single-cell analyses of patient samples are begin-
ning to provide snap shots of changes in cell composition and pathways 
that are associated with diseases such as cancer10–15, chronic inflamma-
tory diseases16,17, Alzheimer’s disease18–20, heart failure21, and sepsis22. 
Because pathophysiological processes within individual cells involve 
different molecular levels, understanding the underlying mechanisms 
requires the integration of current single-cell approaches. LifeTime pro-
poses the integration of several approaches7. This includes combining 
transcriptomics (Fig. 2) with methodologies that provide additional 
information on chromatin accessibility, DNA methylation, histone 
modifications, 3D genome organization, and genomic mutations23–25. 
Future developments will enable the incorporation of single-cell pro-
teomes, lipidomes, and metabolomes, which will add key insights into 
different cellular states and their roles in health and disease. In addi-
tion to specific cell subtypes and the role of cellular heterogeneity, 
it is crucial to investigate the surrounding tissue context and organ 
environment. New spatial ‘-omic’ approaches, particularly spatial 
transcriptomics, include information on the locations of diseased 
cells, their molecular makeup and aberrant cell–cell communication 
within the tissue26–32. Advanced imaging approaches also now enable 
the systematic spatial mapping of molecular components, in situ, within 
cells and of cells within tissues28,33–37. The cellular context, with respect 
to different immune and stromal cell types, extracellular components 
and signalling molecules that contribute to disease progression, will 
help to identify the roles of specific cell types and interactions in dis-
eases32,38–40. The implementation of cell lineage tracing approaches41, 
which link cellular genealogies with phenotypic information about 
the same cells, may help us to understand how populations of cells 
develop dynamically to form the specific architecture of a healthy or 
a diseased tissue.
LifeTime proposes to develop the necessary single-cell methodolo-
gies and end-to-end pipelines (Fig. 2), which will be integrated into 
robust, standardized multi-omics and imaging approaches, and scaled 
to profile hundreds of thousands of patients’ cells7. This will require 
an in-depth analysis of longitudinal human samples obtained from 
patients and cohorts, including European and national clinical trial 
groups as well as initiatives collecting longitudinal biological material 
connected to well-annotated clinical information (Fig. 3). Linking these 
data to clinical outcomes will identify the cellular parameters that are 
permissive to a therapeutic response, for example, during checkpoint 
blockade immunotherapy12,42,43 or treatment of multiple myeloma11. By 
detecting rare drug-resistant cells that are present before11,44 or that 
emerge during treatment45, therapeutic regimens and combinatorial 
treatments can be adapted to improve outcomes.
Handling these large molecular datasets will require sophisticated 
and distributed computational and bioinformatics infrastructures 
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(see ‘Implementation and infrastructure’), as well as the development of 
tools to integrate and ensure the interoperability of different data types, 
including single-cell multi-omics, medical information and electronic 
health records. LifeTime will work with ongoing European and national 
efforts to integrate molecular data into electronic health records and 
to establish standards and interoperable formats to address specific 
disease challenges. This process will promote the development of 
advanced personalized models of disease. To be able to implement rou-
tine longitudinal sampling of patients, we need to develop approaches 
for sampling small biopsies, including liquid biopsies, that will detect 
individual cells or cell-free DNA released from pathological cells before 
and during therapy46. Multi-dimensional descriptors of cell states from 
patients taken from different stages of disease or therapy will be used to 
derive new biomarker sets or to enhance current panels. Collaboration 
with ongoing atlas projects, industrial partners and regulatory authori-
ties will be key for benchmarking and deriving the new standards that 
will enable us to deploy these new methods in the clinic. We hope that 
this will achieve earlier disease detection and guide the appropriate 
selection of drug targets and therapies (Fig. 3).
Unlocking the potential of unprecedented amounts of integrated 
digital information (including molecular data describing how indi-
vidual cells make decisions) requires AI, in particular machine learn-
ing approaches that can identify meaningful molecular patterns and 
dependencies in the datasets47,48. Although such approaches have 
proven very useful when applied to medical imaging data and have 
enabled the identification of subtle disease-associated changes49, medi-
cal imaging cannot capture the full complexity of human physiology 
nor the status of a disease at the single-cell level. High-content imaging, 
together with information about gene expression, chromatin states, 
and protein and metabolic parameters, will contribute to the stratifica-
tion of disease phenotypes. Machine learning and advanced modelling 
approaches will be used to integrate and analyse the different layers 
of cellular activity, and can generate multi-scale and potentially even 
causal models that will allow us to infer regulatory networks and to 
predict present and future disease phenotypes at the cellular level47,50–52 
(Fig. 2).
The deep integration of machine learning technologies with spatial 
multi-omics and imaging technologies and data has the potential to 
usher in a new age of digital pathology to aid in decision-making by 
physicians (Fig. 3). By considering not only anatomical, physiological 
and morphological aspects, but also multidimensional molecular and 
cellular data, it will be possible to provide a more granular represen-
tation of a patient’s disease state to complement the pathologist’s 
slides and bulk measurements in tissues (for example, of mRNA or 
metabolites). We envision as the final goal the incorporation of new 
AI-based decision-aiding systems that will integrate and interpret 
available molecular, cellular, individual disease trajectory and imag-
ing information. Interpretable and accountable AI systems will also 
provide the basis for clinical recommendations. The integration of 
cellular information should lead to a more precise description of a 
patient’s molecular and physiological history, and will guide early 
detection, allow predictive prognosis, and guide recommendations 




























Fig. 1 | Early disease detection and interception by understanding and 
targeting cellular trajectories through time. a, Cells are programmed to 
develop and differentiate along many different specific lineage trajectories 
(blue trajectories) to reach their functional state. When these normal lineage 
processes go awry, it can cause a cell to deviate from a healthy state and  
move towards a complex disease space (coloured manifolds defined by 
multi-dimensional molecular space—including gene expression, protein 
modifications and metabolism), as shown by red trajectories. b, Many diseases 
are detected only at a relatively late stage with the onset of symptoms (red 
trajectory) and when pathophysiological changes can be at an advanced stage 
(red cells). At this point, cells, tissues and organs have undergone extensive and 
often irreversible molecular and physiological changes since the initial events 
that caused them to deviate from a healthy state. Hence, the choice of 
interventions may be limited and often involves harsh or invasive procedures. 
c, Understanding the early molecular mechanisms that cause cells to deviate 
from a healthy to a disease trajectory will provide biomarkers for the early 
detection of disease, and new drug targets and innovative therapies to 
intercept diseases before the onset of pathophysiology and the manifestation 
of symptoms.
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Understanding the cellular origin and aetiology of disease from 
a patient-centred perspective requires systems that faithfully reca-
pitulate key aspects of a patient’s pathophysiology, and render them 
experimentally tractable to test mechanistic hypotheses and predic-
tions. Organoids are an emerging experimental system that allow 
aspects of organ development, regeneration and pathophysiology 
to be modelled3,4,53 (Fig. 2). Derived from adult or pluripotent human 
stem cells, organoids can capture individual features that are unique 
to each patient and can be interrogated molecularly in space and time. 
Importantly, by comparing organoid models from diseased and healthy 
individuals, unique disease features can be extracted even if the specific 
genetic cause of a disease is unknown. Therefore, organoid models 
offer a valuable tool for achieving some of the main goals of LifeTime, 
especially in cases in which repeated access to patient tissues is lim-
ited or impossible (for example, in neurological and neuropsychiatric 
disorders).
Despite their promise, organoids still require substantial devel-
opment to harness their full potential for disease modelling (Fig. 2). 
LifeTime proposes to advance the models to capture the full degree 
of cellular heterogeneity and tissue-specific structural and metabolic 
conditions54, and to incorporate key physiological aspects, such as 
immune responses, vascularization or innervation. Because complex 
interactions between multiple tissues and organs are involved in many 
diseases, it will be necessary to develop tissue engineering principles 
that combine multiple organoids in pathophysiologically relevant 
crosstalk (‘organoids-on-a-chip’). To optimize translational potential, 
LifeTime will engage in standardizing, automating and scaling organoid 
approaches, to allow systematic derivation, propagation and bank-
ing of organoids. Such industrialization is also needed for large-scale 
chemical or genetic perturbations (for example, CRISPR–Cas screens), 
and for elucidating the genetic bases of disease variability and drug 
response at population-relevant scales, in both the preclinical and 
clinical contexts (Fig. 3). The resulting mechanistic dissection, enabled 
by large-scale perturbations, will be used to validate corresponding AI 
models of disease interception and progression.
In addition to organoids, in vivo model systems are necessary to trans-
late the science from the bench to humans. A complex biological system 
is required to study the myriad of host–disease and host–pathogen 
interactions associated with complex diseases, such as infectious 
diseases, cancer or Alzheimer’s disease. The use of animal models is 
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Fig. 2 | Hallmarks of the LifeTime approach to disease interception and 
treatment. The schematic represents the development and integration of key 
technologies for investigating human diseases, as envisioned by the LifeTime 
Initiative. Single-cell multi-omics and imaging technologies will be developed 
for high-throughput applications. Different modalities will be combined to 
provide insight into underlying mechanisms, based on coordinated changes 
between different regulatory molecular layers. Insight into cellular 
genealogies and cellular dynamics will require the integration of lineage 
tracing tools. Technologies will also need to be scaled for clinical deployment. 
The integration and analysis of large, longitudinal multi-omics and imaging 
datasets will require the development of new pipelines and machine learning 
tools. These include the development of causal inference and interpretative 
machine learning approaches to create molecular networks for predictive and 
multiscale disease models. Patient-derived disease models such as organoids 
will be further developed to improve tissue architecture and the incorporation 
of physiological processes such as vasculature, nerve innervation and the 
immune system, to provide models that more faithfully recapitulate disease 
processes. Improved knowledge of disease mechanisms will require the 
application of large-scale perturbation tools to organoids. Tissue–tissue and 
organ–organ interactions will be recreated using microfluidics and 
























































Fig. 3 | Exploiting the LifeTime dimension to empower disease targeting. 
Single-cell multi-omics analysis of patient-derived samples (such as blood or 
tissue) or personalized disease models (for example, organoids and 
experimental disease models) will be profiled longitudinally to cover the 
different disease stages. Large-scale multidimensional datasets will provide 
quantitative, digitalized information that will provide information about the 
decision-making processes of cells. These will be analysed using AI and 
machine learning to arrive at predictive models for disease trajectories, 
providing cellular and molecular mechanisms of disease onset and 
progression. Models will be validated using large-scale perturbation analysis 
and targeted functional studies in disease models, which will be used in an 
iterative process to improve both computational and disease models.
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important for understanding the complex temporal relationships that 
occur in diseases, such as those involving the vasculature, immune 
system and pathogens as well as neuronal networks in the brain. Life-
Time will therefore improve the clinical relevance of animal models 
and make use of approaches in which patient-derived tissues can be 
integrated into in vivo models55–59 to study the dynamics of cellular 
heterogeneity in space and time.
LifeTime, as a community, has the capacity to develop and integrate 
these technologies, which often require expertise and specialized 
instrumentation that are located in distinct laboratories. A coordinated 
effort can achieve the required benchmarking and standardization of 
technologies, workflows and pipelines. This will also ensure that the 
data, software and models generated adhere to FAIR (findable, acces-
sible, interoperable, and reusable) principles60 (see ‘Implementation 
and infrastructure’), are available across national borders, and are in 
full compliance with international legislations such as the European 
General Data Protection Regulation. Moreover, LifeTime will ensure 
that technologies, including AI and organoids, will be developed in 
an ethically responsible way in collaboration with patients, putting 
the patient at the centre (see ‘Ethical and legal issues’).
Identification of medical priorities
LifeTime has initiated a mechanism, called Launchpad, to systematically 
identify medical challenges that can be addressed through LifeTime’s 
approach and have a direct effect on patient care. Initially, the focus has 
been on five disease areas that are a substantial burden to society: can-
cer, neurological and neuropsychiatric disorders, infectious diseases, 
chronic inflammatory diseases and cardiovascular diseases. Other dis-
ease areas will be continuously monitored (for example, rare Mendelian 
diseases and metabolic diseases), and research programmes initiated 
as technologies and infrastructures develop. The LifeTime Launchpad 
has defined several criteria to identify the medical challenges. These 
include: societal impact (including incidence and prevalence, disease 
severity, economic impact and the pressing need for new and more 
efficient clinical treatments and early detection), evidence for cel-
lular heterogeneity that limits current clinical avenues, availability 
of samples from biobanks, relevant preclinical models, existence of 
patient cohorts including those enabling longitudinal studies, clinical 
feasibility and ethical considerations, as well as alignment with national 
and EU funding priorities. Subsequently, multidisciplinary working 
groups, including clinicians, in each disease area have used these cri-
teria to define the following disease challenges and to develop ten-year 
roadmaps to address them in the LifeTime SRA7.
Despite cancer broadly covering hundreds of individual tumour 
types, there are critical knowledge gaps that are common to all cancer 
entities, including the mechanisms of early dissemination and therapy 
resistance. Metastatic dissemination of a subpopulation of cancer cells 
is a leading cause of death in almost all cancer types. Successful treat-
ment of advanced and metastasized forms of cancer remains difficult, 
despite the development of targeted therapies and immunotherapies, 
owing to the emergence of drug or therapy resistance. To address these 
medical priorities, LifeTime recommends focusing on understand-
ing the cell types and states—malignant cells and their microenviron-
ment—that are involved in early stages of cancer dissemination, and 
the reprogramming of cellular states during disease and their effect 
on resistance to therapies.
For neurological disorders, a major challenge is a lack of under-
standing of the early events in disease onset to enable the develop-
ment of disease-modifying therapies. The lack of access to longitudinal 
samples from patients necessitates the establishment of cohorts of 
patient-derived disease models to understand the cellular heterogene-
ity associated with disease. The discovery of pathways and biomarkers 
that will allow the stratification of patients on the basis of the cellular 
mechanisms that drive a disease will make it possible to design new 
clinical trials to reevaluate drugs that were previously tested without 
such stratification, and to broaden the drug target portfolio.
As seen during the coronavirus disease 2019 (COVID-19) pandemic, 
it is important to be able to understand infection mechanisms and 
the host response in order to rapidly identify the most likely effective 
treatment for an infection. At the same time, the continuous rise of 
antimicrobial resistance requires the discovery of new therapeutic 
strategies. A key medical challenge for infectious diseases is to under-
stand the cellular response to infections and to develop precision, 
immune-based therapeutic strategies to combat infections.
Chronic inflammatory diseases impose a high burden owing to their 
long-term debilitating consequences, which result from the structural 
destruction of affected organs or tissues. Current therapies treat the 
symptoms but do not cure or fully control the chronic inflammatory 
pathophysiology. While different targeted therapies exist, they are 
expensive and their success is limited by high rates of non-response 
to treatment. Consequently, there is an urgent need to explore and 
understand how cellular heterogeneity contributes to the pathology 
of inflammatory diseases61 and how this relates to the predicted course 
of disease and the response of a patient to one of the numerous avail-
able therapies.
Many cardiovascular and metabolic diseases lack effective therapies 
owing to a lack of knowledge of their underlying causes and the link 
between abnormal cardiac cell structure or function and pathophysiol-
ogy. The identified medical priority is to understand the cellular and 
molecular mechanisms involved, in order to enable early diagnosis 
and the design of new mechanism-based therapies for precise clinical 
treatment.
The LifeTime disease roadmaps can be divided broadly into three 
phases7: first, immediate research into the identified medical challenges 
using established, scaled single-cell technologies, computational tools 
and disease models; second, the development of new technologies 
that are required to address specific medical challenges, including 
the development of spatial multi-omics and imaging approaches and 
advanced patient-derived model systems for longitudinal analyses; and 
finally, the application of these next-generation technologies to the 
longitudinal analyses of patient samples, or patient-derived models, 
combined with machine learning to generate patient trajectories and 
predictive models of disease. The resulting predictions and biomark-
ers will be validated in prospectively collected patient cohorts within 
clinical trials that will also include longitudinal liquid biopsies. The 
routine clinical use of predictors and biomarkers for risk stratification 
of patients and resulting interventions—where feasible—is the pre-final 
step. The final step is the extension of predictors and biomarkers to the 
analysis of large longitudinal patient cohorts, such as national cohorts, 
for developing secondary and tertiary prevention approaches based 
on the new biomarkers.
During the implementation of these roadmaps, the initiative will 
establish an experimental design working group to develop system-
atic procedures to ensure that research samples are acquired from 
diverse cohorts (including age, sex, and ethnicity). This will require 
the development of strict criteria for the inclusion of samples and 
to ensure appropriate coverage of critical metadata. They will also 
define standardized procedures for the acquisition and processing 
of samples from different pathology sites (depending on the disease 
area). It is envisaged that during disease challenge pilot projects, an 
experimental design oversight body will determine, using early data, 
the number of diseases that should be studied as the initiative devel-
ops, with recommendations on the sample sizes required to obtain 
sufficient statistical power.
Implementation and infrastructure
The scale of the data that will be generated and analysed, the 
cross-disciplinary and international structure, and the ambition of 
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LifeTime to pioneer novel analytics using AI, place LifeTime in an excel-
lent position to shape the next generation of computational infrastruc-
ture for medical and biological data in Europe. This will require close 
interaction with and evolution of the established European infrastruc-
ture (Fig. 4), such as the European Open Science Cloud (EOSC) and 
high-performance computing infrastructures through the European 
High-Performance Computing (EuroHPC) initiative. LifeTime will also 
interact with related European Life Sciences Research Infrastructures62 
to create added value and to avoid duplication of effort in strategies and 
tools for sharing and accessing data and the development and applica-
tion of standards. As medicine is inherently decentralized, LifeTime will 
also help to connect EU medical systems and develop large federated 
European data infrastructures.
Fragmentation of research across borders, disciplines and time-
frames needs to be overcome. The generation of data and development 
of technology by LifeTime will be harmonized across expert groups 
and centres, allowing the results to be quickly applied in clinics. Thus, a 
coordinated approach is required that integrates the multidisciplinary 
expertise of single-cell technologies, data science, and organoids as 
well as in vivo models across Europe. It must also engage clinicians 
and patients to achieve medical impact. To address these challenges, 
LifeTime proposes a multidisciplinary network of LifeTime Centres 
(Fig. 4) with different complementary thematic clusters across Europe, 
each working in close association with hospitals. These connected, 
flexible innovation nodes will share resources, gather the necessary 
critical mass for global competitiveness, and be open for collaboration 
with the entire scientific community. LifeTime Centres should deliver 
a number of key functions:
∙ Serve as platforms for the development and advancement of break-
through technologies for single-cell research in -omics and imaging, AI 
(in particular machine learning), and experimental and computational 
disease models.
∙ Closely and actively collaborate with patients, clinicians, hospitals 
and healthcare systems, in some cases with a specific disease focus.
∙ Set standards in data generation, standardization and management, 
implementing FAIR principles.
∙ Set standards in ethical, legal and societal issues (ELSI) programmes 
by working together in multidisciplinary teams aimed at responsible 
research and innovation.
∙ Offer opportunities to collaborate, test and benchmark new meth-
odologies and analysis methods; for example, in adaptive experimental 
design.
∙ Offer unique opportunities to industry to translate recent knowl-
edge and novel technologies from the laboratory to the market.
∙ Provide an early access programme to new technologies developed 
by companies.
∙ Function as open, interconnected education hubs, delivering train-
ing in the new technologies to researchers, scientific personnel and 
clinicians, as well as providing engagement activities for patients and 
the public.
LifeTime aims to analyse data that are inherently distributed across 
different clinical centres in different countries, which is a substantial 
challenge. These data are usually not accessible outside a national, 
regional clinical care system or specified data ‘safe havens’; when they 
are accessible, accredited systems are often required for storing the 
data and information governance may be at the hospital, federal or 
international level. This means that a federated approach is the only way 
to access and integrate information from various European healthcare 
systems. Thus, the LifeTime data and computational network, building 
on cloud technologies, will provide the necessary capacities to enable 
federated analytics across the LifeTime centres and will provide a tech-
nical and legal framework for integrating core information structures, 
multi-omics assays, imaging, AI and machine learning technologies, 
and health records (Fig. 4). A joint Data Coordination Centre, following 
a multi-level approach, will ensure transparent data access control, 
compatibility and standardization. Within this framework, LifeTime 
will also coordinate and pioneer open data sharing and reuse and col-
laboration, including models of access before publication of data.
To start this cooperative LifeTime Centre network, the initiative can 
build on initial developments and programmes by LifeTime members 
in a number of European countries; for example, the VIB Single-cell 
Accelerator Programme in Belgium, the Berlin Cell Hospital/Clinical 
Single-cell Focus in Germany, the UK’s Sanger/EBI/Babraham Single 
Cell Genomics Centre, and the LifeTime Single-Cell Centre in Poland. 
To avoid duplication and lack of standardization, the LifeTime Cell 
Centre network should be coordinated through an entity or frame-
work that optimizes coordination and support to achieve the LifeTime 
vision. Funding for specific research projects that involve one or more 
LifeTime Centres could come from a portfolio of private and public 
funding opportunities, on both the national and pan-European levels. 
The network will interact closely with key European efforts and will 
contribute to EU strategies and programmes.
Interaction with industry and innovation
Collaborations with the private sector will be key for the rapid transla-
tion and delivery of technologies, instrumentation, diagnostics and 
therapies (Fig. 4). Currently, more than 80 companies support Life-
Time’s vision. These span multiple sectors as well as industrial associa-
tions and networks such as the European Federation of Pharmaceutical 
Industries (EFPIA) and the Euro-BioImaging Industry Board (EBIB).
The transformation of breakthrough discoveries into solutions to 
improve the health of European citizens will involve several crucial 
steps. These include the creation of a unifying framework that fosters 
and streamlines pre-competitive interactions between academia and 
industry at the interfaces of computer science, single-cell biology, 
-omics, imaging, patient-derived disease modelling and precision 
medicine. A large-scale collaboration platform across Europe should 
be developed that provides umbrella agreements, regular meetings, 
dual training of early-career scientists in academia and industry, and 
exchange programmes. This will enable joint projects between public 
and private sectors that span the entire biomedical innovation cycle 
from discovery research and technology development to implementa-
tion in hospitals and the healthcare industry.
Cross-sectoral collaborations between small, medium-size and large 
companies with different development timelines and distinct business 
models is crucial to stimulate innovation. To expedite the identification 
of, and investment in, emerging technologies developed in academic 
and industrial laboratories, successful local initiatives such as tech 
watch and accelerator programmes (for example, the VIB Single-cell 
Accelerator) should be scaled and coordinated at the EU level. LifeTime 
aims to create a networking and match-making platform for individuals 
and academic and industry organizations that share the goal of develop-
ing and integrating breakthrough technologies and applying them in 
the clinic to benefit patients. Further measures could foster innovation 
and entrepreneurship. For example, a pre-seed, pre-incubator funding 
scheme based on competitive calls to support start-up or technology 
transfer ideas.
The creation of a dedicated European ecosystem is also essential. 
This will require additional key measures, such as the development 
of enabling digital environments and the promotion of early disease 
interception with all necessary stakeholders (for example, patients, 
regulators, payers, and others), as described in the LifeTime call for 
action launched in December 2019 (https://lifetime-initiative.eu/
make-eu-health-research-count/).
Ethical and legal issues
The implementation of LifeTime’s vision triggers relevant ethical 
questions from all societal groups that are directly affected by the 
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project (patients, clinicians and scientists), and from society in gen-
eral. LifeTime aims to pioneer a real-time or parallel ELSI programme 
that will predict, identify, monitor and manage the ethical impact of 
the biomedical innovations that arise from research and technology 
development, ensuring that implementation follows ethical guidelines. 
LifeTime’s ELSI programme can be used as a testing ground for other 
international interdisciplinary initiatives (Fig. 4). Ethical issues will be 
identified and managed as early as possible, and the programme will 
ensure that ethical and research integrity guidance is implemented 
throughout the entire research process to stimulate positive effects 
and mitigate negative ones63.
Specialists in bioethics, public engagement, ethics of technology and 
lawyers have identified LifeTime’s ethical and societal priority areas. 
These include questions related to the derivation, storage and use of 
organoids, the use of AI, data ownership and management, anonymiza-
tion of data, equity of access to such revolutionary medical care, the 
definition of health and illness, and transparent science communica-
tion to society64. To initiate a relationship of trust with the public, we 
will include diverse modes of communication and engagement, for 
example through art, citizen science and public dialogue, contributing 
to scientific literacy, and promoting individual critical thinking and 
public participation in decision-making processes.
Education and training
The introduction of interceptive medicine into clinical practice in paral-
lel with a multidisciplinary research programme will require capacity 
building in health and research systems, and substantial deployment of 
technology in clinics. This will lead to a collaborative, fast-developing 
and interdisciplinary environment in research and in hospitals, which 
will require new training inputs. To respond to these needs, LifeTime 
will create an Education and Training Programme, ensuring the sus-
tainable application of new technologies and the implementation of 
new medical and scientific approaches (Fig. 4). Importantly, this will 
be done in an integrative scheme that intersects the multiple LifeTime 
disciplines and areas of action: disruptive technologies applied to medi-
cal challenges, technology transfer and innovation, research integrity, 
data management and stewardship, ethical and societal issues, com-
munication and emotional skills, or management of medico-scientific 
and collaborative projects.
Each LifeTime training activity will be based on multi-lateral educa-
tion: basic researchers will teach other researchers and clinicians about 
the potential of the technological solutions, while clinicians will teach 
researchers about the clinical needs and biological challenges of the 
diseases in focus. This will strictly follow the idea of bench to bedside 
and back. The programme will have an inclusive philosophy to ensure 
that it can provide training to the wider community, including research-
ers, clinicians, technical operators, managers and staff of technology 
platforms, as well as administrators, patients and the lay public.
LifeTime envisions the organization of cycles of colloquia and out-
reach activities to inform the public, the formulation of short-term 
courses compatible with a culture of lifelong learning and adaptability, 
and interdisciplinary Masters and PhD programmes. Through educa-
tion and training, LifeTime will engage and inform society, will develop 
Community interactions














LifeTime Cell Centre Network
Fig. 4 | Blueprint of the LifeTime Initiative. LifeTime proposes a large-scale 
research initiative to coordinate national efforts, and to foster collaboration 
and knowledge exchange between the public and private sectors. LifeTime 
recommends the implementation of several programmes. (1) A network of Cell 
Centres to support the European Community. The interdisciplinary centres 
would complement each other’s strengths and expertise in the three LifeTime 
technology areas and operate in tight association with hospitals, integrating 
technology development with clinical practice. The connected but 
geographically distributed nodes would serve as both innovation hubs with 
strong links to industry and open education and training centres. Community 
coordination would avoid duplication of effort and increase effectiveness; this 
model requires funding instruments for a central coordination body. (2) The 
LifeTime research and technology integration programme includes both 
technology development and integration and the discovery of disease 
mechanisms and clinical applications. (3) Medical and biological data 
management platform. (4) Programmes fostering industry and innovation. (5) 
Education and training. (6) Ethics and societal engagement.
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new professional curricula and will train a new generation of highly 
skilled medical scientists and support staff, in order to foster scien-
tific and medical excellence in an ethical, responsible and inclusive 
framework.
Impact on medicine and healthcare
Medicine and healthcare are rapidly expanding pillars of our economy. 
EU countries collectively spend more than €1,400 billion per year on 
healthcare for their 500 million citizens. Given the dimensions and 
spiralling healthcare costs associated with an ageing population, 
these numbers will continue to increase unless we can mitigate the 
damaging effects of ageing. We expect that coupling current health 
monitoring with early detection and disease interception will have a 
major economic impact. In Europe, 20% of the population will soon be 
over 65 years old, with an age distribution that will continue to change 
until 12% are over 80 years old in 208065. Given the prevalence and cost 
of caring for people with degenerative conditions and the increase in 
chronic lifestyle-induced diseases, the knowledge and technologies 
developed by LifeTime are urgently needed to detect these diseases 
earlier, and to avoid their worst manifestations. LifeTime would also 
have an impact in the era of unexpected pandemics such as COVID-19 
by rapidly determining the cellular and molecular basis of the disease. 
This would identify potential therapeutic strategies for patient sub-
groups as well as representing a starting point for the development 
of effective new therapies.
One of healthcare’s largest outstanding issues is that many patients 
do not respond to commonly prescribed treatments. Whereas 
well-controlled randomized clinical trials provide evidence for the 
statistical utility of a given therapy, in practice often many patients 
must be treated before a single patient will show a measurable benefit. 
Other patients may not benefit at all or even be harmed66, leading to 
an economic loss that is estimated to be in the hundreds of billions 
of Euros per year. The variable therapeutic responses that originate 
from the cellular and genetic heterogeneity that exists in cancer and 
other complex diseases, contributes not only to the failure of treat-
ments, but also to the rising cost of drug development, which is cur-
rently estimated at around €1–2 billion per drug. In silico models for 
disease trajectories generated by LifeTime will enable the integration 
of personal genetic and lifestyle information into predictive models of 
disease course. This will allow physicians to determine and implement 
optimal therapeutic strategies that are tailored to the individual (preci-
sion medicine) with sophisticated timing of disease interception. The 
knowledge gained will also contribute to more appropriate selection 
of patients for clinical trials.
Outlook summary
Recent advances in key single-cell technologies, AI and patient-based 
experimental systems, such as induced pluripotent cells and organoids, 
have set the stage for their integration and deployment to improve mech-
anistic molecular understanding, prediction, and treatment of disease 
onset and progression. Patients will benefit from cell-based medicine 
through the earlier detection of diseases at a stage where they can be 
effectively intercepted. The integrated technologies will enable the selec-
tion, monitoring and, if necessary, modification of therapeutic strategies 
for an individual to improve clinical outcomes based on high-resolution 
cellular information. Within the next decade, the obtained molecular 
mechanistic information has the potential to revolutionize drug discov-
ery processes and clinical trial design, and eventually to be incorporated 
into clinicians’ daily decision-making processes. As the LifeTime commu-
nity continues to grow, new individuals, institutions and companies are 
encouraged to join and contribute to establishing a European platform to 
implement single-cell and data-driven medicine to address the growing 
burden of complex and chronic diseases.
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